Dupixent Lymphoma: When Eczema Wasn’t Eczema

Last updated: October 2026

For some people, Dupixent seemed to work at first. Their eczema calmed down, and then it came back in a different way. Months or years later, a biopsy showed it had never been only eczema. It was cutaneous T-cell lymphoma (CTCL), a cancer that starts in the skin. If you are facing a Dupixent lymphoma diagnosis after years of eczema care, the practical steps below may help you move forward with more clarity.

This post is about that experience. It explains why Dupixent lymphoma cases often begin with a rash that looked like eczema, what people commonly go through, and where to turn for answers and support.

A rash that looked like eczema

CTCL is a lymphoma of T-cells, a type of white blood cell that lives in the skin. The most common form is mycosis fungoides. The National Cancer Institute describes its early stage as a “thin, reddened, eczema-like rash.”

That is why CTCL is so hard to catch early. It can be itchy, red and scaly. It may show up on the hips, buttocks, thighs or trunk. It may even improve for a while with creams. To a busy clinic, and to the person living with it, it can look like just another eczema flare.

Because of this overlap, some people with CTCL are treated for eczema or dermatitis for a long time before a biopsy gives the real answer.

A common pattern: better, then different

Every person’s path is different. But patients, doctors and lawsuits describe a similar pattern. The example below is a general picture, not one real person’s story.

It gets better

Someone with long-standing eczema starts Dupixent. Within weeks or months, the itching eases. Sleep improves. For the first time in years, their skin feels calmer.

Something changes

Later, certain patches stop responding. They stay in the same spots instead of moving around. Some turn thicker, pinker or more sharply outlined. New areas appear. The person may be told it is a flare, a reaction to the drug or eczema that needs more time.

The biopsy

Eventually, a dermatologist takes a skin biopsy. Sometimes the first one or two come back as “dermatitis.” NCI notes that more than one biopsy is often needed to diagnose mycosis fungoides. When the answer finally comes, it is CTCL.

The questions

After the shock, the same questions come up again and again. Did I have this all along? Did the drug cause it or make it worse? Why didn’t anyone warn me?

Did Dupixent cause it, or reveal it?

No one can answer that for a single person yet. Researchers are looking at several possibilities:

• Missed diagnosis: Some people may have had early CTCL that was mistaken for eczema before they ever started Dupixent.
• Speeding up: Some doctors have asked whether the drug may allow hidden CTCL to progress faster.
• New cancer: Plaintiffs claim the drug may cause CTCL in some users.

A 2024 study of about 45,000 eczema patients found higher odds of CTCL in those treated with dupilumab, MDedge reported. Studies like this show a link in the data, not proof of cause. Other studies have not found a clear increase.

The FDA listed CTCL as a potential safety signal for Dupixent in its October–December 2024 report. It said it is evaluating whether action is needed. The drug has not been recalled.

Living with the diagnosis

A CTCL diagnosis brings a lot at once: appointments, new terms, new treatments and big feelings. Some things that may help:

• Find a CTCL-experienced team. CTCL is rare. Many people see a dermatologist and an oncologist at a cancer center that treats cutaneous lymphoma often.
• Ask about your stage. NCI describes four stages, based on how much skin is involved and whether lymph nodes, blood or organs are affected. Your stage shapes your treatment choices.
• Care for your skin and itch. Itching can be one of the hardest parts. Ask your team about itch relief and skin care that fits your treatment.
• Get support. The Cutaneous Lymphoma Foundation offers patient education, emotional support, networking groups and help with financial and caregiver questions.

Questions to bring to your next visit:

• “What stage is my CTCL, and what does that mean for treatment?”
• “Should I keep taking Dupixent, switch or stop?”
• “Could my earlier biopsies be reviewed again?”
• “How often will I need skin checks, scans or blood tests?”

Bring a friend or family member if you can. A second set of ears helps when there is a lot of new information.

It is also normal to feel angry or betrayed, especially if you were treated for eczema for years. Talking with a counselor, support group or trusted friend can help.

Protecting your options while you focus on your health

Your health comes first. But a few simple steps now can keep your options open later.

• Save your pathology reports, including early biopsies that said “eczema” or “dermatitis.”
• Ask your pharmacy and insurer for a full Dupixent fill history.
• Keep dated photos of your skin over time.
• Write down when symptoms changed while you were on Dupixent.
• Don’t stop or change any medicine without talking to your doctor.

Federal CTCL lawsuits against the makers of Dupixent are now grouped in MDL No. 3180 in New Jersey. The companies deny the claims, and no case has been tried or settled. Filing deadlines vary by state and claim type, and in some states the clock may start around the time of diagnosis.

For families and caregivers

Caregivers often notice changes first. They see the patches that won’t heal or the itching that keeps someone up at night. If you are caring for someone on Dupixent:

• Help keep a simple symptom and photo log.
• Go to appointments and write down what the doctor says.
• Ask whether a second opinion at a cancer center makes sense.

If a loved one died from CTCL after using Dupixent, you may have questions about a wrongful death claim. Deadlines for those claims also vary by state.

Understanding CTCL Treatment After a Dupixent Lymphoma Diagnosis

After the shock of a Dupixent lymphoma diagnosis, the next question is usually, “What now?” Treatment for CTCL depends on the type, the stage and your overall health. Many people with early disease start with treatments aimed at the skin.

The National Cancer Institute lists several standard treatments for mycosis fungoides and Sézary syndrome. Your care team will explain which ones fit your situation.

Treatments aimed at the skin

• Topical corticosteroids: Creams or ointments that NCI says are used to relieve red, swollen and inflamed skin.
• Light therapy: Treatment with ultraviolet A (UVA) or ultraviolet B (UVB) light, often given in a clinic several times a week.
• Photodynamic therapy: A drug combined with a special light to target cancer cells in the skin.
• Topical chemotherapy: Medicine applied directly to the skin.
• Radiation: This can include total skin electron beam therapy, which treats the surface of the skin across the whole body.

Treatments that work throughout the body

• Retinoids and other drugs: Such as bexarotene, and a group called HDAC inhibitors.
• Immunotherapy: Treatments such as interferon that use the immune system to fight cancer.
• Targeted therapy: Antibody drugs such as mogamulizumab and brentuximab vedotin.
• Chemotherapy: Medicine given by mouth or by vein.
• Stem cell transplant: High-dose treatment followed by a transplant, used in some advanced cases.

Clinical trials

NCI notes that patients can join clinical trials before, during or after starting treatment. Ask your oncologist whether a trial might be right for you. Trials test new treatments and can offer options not yet widely available.

Treatment for a Dupixent lymphoma diagnosis is a medical decision, not a legal one. Your care team, not a lawsuit, should guide every choice about your therapy.

Coping With a Delayed Diagnosis

Many people with a Dupixent lymphoma diagnosis say the hardest part is looking back. They wonder how long the cancer was there and whether it could have been found sooner. These feelings are common and understandable.

Feelings you may have

• Anger at the drug, the doctors or yourself.
• Grief for the years spent treating the wrong condition.
• Fear about the future and what your stage means.
• Relief at finally having an answer.
• Confusion about whom to trust now.

You may feel several of these at once, or they may come in waves. None of them is wrong, and none of them means you are handling a Dupixent lymphoma diagnosis badly.

Small steps that can help

• Write your questions down as they come up, and bring them to each visit.
• Ask your cancer center about counseling or social work services.
• Connect with others who have CTCL through a patient support group.
• Set limits on how much you read online, especially late at night.
• Lean on one or two people you trust to help with appointments and paperwork.

Finding others who understand

CTCL is rare, so you may not know anyone else who has it. Patient groups, including those run by the Cutaneous Lymphoma Foundation, can connect you with people who have lived through a Dupixent lymphoma diagnosis or a similar path from eczema to CTCL. Hearing how others coped can make you feel less alone.

Talking with the doctor who treated your eczema

Some people want to talk with the dermatologist who first treated them. That conversation can bring closure or raise new questions. You can ask how the diagnosis was reached and what signs to watch for now. Keep the focus on your care going forward.

Work, Money and Insurance After a Dupixent Lymphoma Diagnosis

A Dupixent lymphoma diagnosis affects more than your health. Treatment schedules, travel to a cancer center and fatigue can all make work and money harder to manage. Planning early can ease some of the strain.

Time off from work

The Family and Medical Leave Act may help. According to the U.S. Department of Labor, eligible employees can take up to 12 workweeks of unpaid, job-protected leave in a 12-month period for a serious health condition. Group health coverage continues during that leave on the same terms.

Not every worker qualifies. The DOL says employees generally must have worked for a covered employer for at least 12 months and at least 1,250 hours in the past year. Ask your human resources office how leave works where you are employed.

Insurance questions

• Ask your insurer which cancer centers and doctors are in your network.
• Request pre-approval for treatments that need it, such as light therapy or new drugs.
• Keep every insurance letter, including denials. You can usually appeal a denial.
• Ask the cancer center’s financial counselor about payment plans or assistance programs.

Tracking costs

Keep a simple record of medical bills, travel to appointments and time missed from work. This helps with budgeting and taxes. It can also help a participating law firm understand how a Dupixent lymphoma diagnosis has affected your life, if you decide to ask about a claim.

Telling Family and Friends About a Dupixent Lymphoma Diagnosis

Sharing a Dupixent lymphoma diagnosis can feel almost as hard as hearing it. Many people worry about scaring loved ones or being asked questions they cannot answer yet. You get to decide who to tell, when and how much.

Start with a short version

A few simple sentences are often enough at first. For example: “My rash turned out to be a rare skin lymphoma called CTCL. My doctors are working on a treatment plan, and I will share more when I know more.”

Explain that it is not contagious

Some people hear “skin cancer” or “rash” and worry about catching it. CTCL is a cancer of white blood cells. It cannot spread from person to person through touch.

Give people a way to help

• Driving to appointments or light therapy sessions.
• Picking up prescriptions or groceries.
• Sitting in on doctor visits to take notes.
• Helping keep track of bills, records and insurance letters.

People often want to help but do not know how. A specific request is easier to say yes to. If talking about a Dupixent lymphoma diagnosis with children, keep the message simple and honest, and reassure them that you have a team taking care of you.

Keeping a Dupixent Lymphoma Care Notebook

Between appointments, test results and new medicines, details are easy to lose. A care notebook keeps them in one place. It can be a paper binder, a notes app or a shared document with a trusted family member.

• Your team: Names and phone numbers for each doctor, nurse and pharmacy.
• Your diagnosis: The type and stage of CTCL, and the date of your diagnosis.
• Your treatments: What you started, when, and any side effects.
• Your skin: Dated photos and short notes on changes.
• Your questions: A running list to bring to each visit.
• Your Dupixent history: When you started, when you stopped, and how your skin responded along the way.

A notebook like this helps every new doctor understand your story quickly. It also keeps your Dupixent lymphoma timeline clear if you later decide to talk with a participating law firm.

Asking for a Second Look at Earlier Biopsies

If you had biopsies before your CTCL diagnosis that were read as eczema or dermatitis, you may wonder what they really showed. In many cases, the original slides and tissue blocks can be reviewed again.

Why a re-review can help

A second pathologist, often at a cancer center, can look at older slides with fresh eyes and with knowledge of your current diagnosis. This can help your care team understand how long the disease may have been present. It may also help answer some of the questions that come with a Dupixent lymphoma diagnosis.

How to ask

1. Ask your oncologist or dermatologist whether a review of earlier slides would be helpful.
2. Find out which lab read each earlier biopsy. The pathology report usually lists it.
3. Ask the lab to send the slides to the reviewing center, or to keep them on file if you are not ready yet.
4. Request a copy of any new report for your records.

What a re-review cannot do

Even a careful second look may not give a clear answer. Early CTCL can look like ordinary inflammation under the microscope, which is why it is so often missed. A re-review is one piece of information, not a final verdict on what caused a Dupixent lymphoma diagnosis.

Labs keep slides and blocks for set periods, so it can help to ask sooner rather than later. Keeping these samples safe can matter for your care and, if you choose, for a possible Dupixent lymphoma claim.

Frequently asked questions

How Direct2Attorney can help

If your eczema turned out to be CTCL after using Dupixent, you don’t have to sort out your options alone. We can connect you with a participating law firm that may review your situation at no cost. Visit our Dupixent lawsuit page to learn more. For signs to watch, read when a Dupixent rash needs a biopsy.

A Dupixent lymphoma diagnosis can change how you look at years of treatment. Getting clear answers, from your doctors and about your rights, is a good next step.

Direct2Attorney is a legal marketing and referral service, not a law firm. This article is general information, not legal advice. Submitting information does not create an attorney-client relationship.